
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, share their thoughts on sequencing disease-modifying therapies when treating patients with multiple sclerosis.
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, share their thoughts on sequencing disease-modifying therapies when treating patients with multiple sclerosis.
Episode 28 of the AUPN Leadership Minute features Donald S. Higgins, MD, of the VHA; and Gabriele C. De Luca, MD, DPhil, FRCPath, FAAN, of University of Oxford. [WATCH TIME: 5 minutes]
The professor of medicine at the University of Manitoba discussed the need to change how multiple sclerosis is characterized, and how aging contributes to increased disease progression. [WATCH TIME: 4 minutes]
The pediatric epilepsy specialist at Weill Cornell Medicine in New York City spoke on how meetings such as the 2022 AES Conference bring clinicians together as well as how parents motivate them to advance pediatric epilepsy research. [WATCH TIME: 6 minutes]
The chief executive officer and co-founder of Linus Health provided perspective on the state of clinical trials for Alzheimer disease, and how technology can play a major role in advancing therapeutics going forward. [WATCH TIME: 4 minutes]
The assistant professor of neurology at Massachusetts General Hospital and Harvard Medical School spoke about the high risk of epilepsy for the older population at the 2022 AES annual meeting. [WATCH TIME: 1 minute]
Neurology News Network for the week ending December 10, 2022. [WATCH TIME: 4 minutes]
The professor of neurology at Washington University School of Medicine in St. Louis spoke about the field of newborn sleep and epilepsy based on a special lecture from the 2022 AES annual meeting. [WATCH TIME: 3 minutes]
The chief medical officer of Alzheon provided perspective on new phase 2 findings assessing the investigational agent ALZ-801 in patients with early Alzheimer disease and a genetic predisposition. [WATCH TIME: 5 minutes]
Advanced practice practitioners discuss how they assess treatment response and patient adherence in insomnia, and considerations for changing treatment.
Drs Wendy Wright and Debra Davis provide an overview of phase 3 trial data for the most recently FDA-approved DORA, daridorexant, for the treatment of insomnia.
The pediatric epilepsy specialist at Weill Cornell Medicine spoke about how the Pediatric Epilepsy Learning Healthcare System has helped with gathering data at the 2022 AES Conference. [WATCH TIME: 6 minutes]
The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the way to attack Alzheimer agitation and why drug solutions often fall short. [WATCH TIME: 3 minutes]
The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine detailed the need for improved biomarkers of dementia with Lewy bodies and whether research in Alzheimer disease helps propel the field. [WATCH TIME: 3 minutes]
The behavioral neurologist at the Barrow Neurological Institute detailed the significance of low rates of ARIA found in lecanemab, and the direction of anti-amyloid therapies in the future. [WATCH TIME: 4 minutes]
The professor of neurology at Washington University in St. Louis, spoke about sleep-wake patterns in epilepsy based on a special lecture from the 2022 AES Annual meeting. [WATCH TIME: 6 minutes]
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, examine the safety of sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis.
An expert panel talks about the preservation of brain health regarding the use of sphingosine 1-phosphate receptor modulators to treat multiple sclerosis.
The associate professor of neurology at the University of Calgary spoke about advancing epilepsy care through patient-oriented research at the 2022 AES Annual Meeting. [WATCH TIME: 6 minutes]
The associate professor of neurology at Wayne State University in Detroit, Michigan, spoke about expensive antiseizure medications for epilepsy along with spending for Medicare and Medicaid at the 2022 AES Annual Meeting. [WATCH TIME: 4 minutes]
The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center provided perspective on the strides made with detection and treatment of infantile spasms. [WATCH TIME: 3 minutes]
The professor of neurology at Washington University in St. Louis, and the president of the American Epilepsy Society, shared his perspective on John Hughlings Jackson’s observations of epilepsy in the brain and how it can inform modern practice. [WATCH TIME: 5 minutes]
The assistant professor in the department of pharmacology and chemical biology at Emory University School of Medicine spoke about immune cells in epilepsy based on his special lecture at the 2022 AES Annual Meeting. [WATCH TIME: 4 minutes]
The associate clinical professor of neurology at OSU Wexner Medical Center discussed the state of interdisciplinary care for individuals with epilepsy, and how these care teams operate. [WATCH TIME: 2 minutes]
The professor of neurology at NYU Grossman School of Medicine and chief medical officer of the Epilepsy Foundation discussed the critical need to ensure the proper classification of seizures when enrolling patients in clinical trials. [WATCH TIME: 4 minutes]
The behavioral neurologist at the Barrow Neurological Institute provided perspective on the safety profile of lecanemab and the importance of a low incidence of amyloid-related imaging abnormalities. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending December 3, 2022. [WATCH TIME: 3 minutes]
The senior research scientist at the Institute for Systems Biology spoke about changing the perception of clinical trials for Alzheimer disease research based on the COCOA trial presented at the 2022 CTAD conference. [WATCH TIME: 2 minutes]
The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the treatment differences and unmet needs between dementia with Lewy bodies and Alzheimer disease. [WATCH TIME: 4 minutes]
The senior research scientist at the Institute for Systems Biology spoke about his presentation on multimodal clinical and lifestyle interventions that improve cognitive outcomes at the 2022 CTAD conference. [WATCH TIME: 4 minutes]